This study found that pretreating concentrated growth factor with a 640 nm laser increased CD34+ stemcell activation and improved hair growth outcomes in androgenetic alopecia patients compared to non-pretreated CGF.
This study found that CD34- melanocyte stemcells regenerated pigmentation more efficiently, while CD34+ cells showed potential for neuron myelination, suggesting different therapeutic applications for each population.
54 citations
,
January 2009 in “British Journal of Dermatology”
This study found that in scarring alopecia, stemcells are differentially localized, suggesting that both inner and outer root sheath stemcells, rather than just follicular bulge stemcells, are involved.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stemcells, but minoxidil and finasteride are still the main treatments.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.